Publications

Adverse cutaneous reactions to the new second-generation tyrosine kinase inhibitors (dasatinib, nilotinib) in chronic myeloid leukemia.
J Am Acad Dermatol 2013 Nov;69(5):839-40
Department of Dermatology, Referral Centre for Auto-immune and Toxic Bullous Diseases, Henri-Mondor Hospital (Assistance Publique -Hôpitaux de Paris), UPEC, F-94010 Créteil, France.


OF